Company Overview

Sera Prognostics, Inc. is a U.S.-based biotechnology company focused on developing and commercializing blood-based proteomic tests intended to improve maternal and neonatal health outcomes. The company operates within the women’s health, diagnostics, and precision medicine industries, with a primary emphasis on predicting risks associated with preterm birth and pregnancy complications. Its principal commercial product is the PreTRM test, a commercially available maternal blood test designed to identify pregnant individuals at increased risk of spontaneous preterm birth before clinical symptoms emerge. Revenue generation has historically been tied to testing services, collaboration arrangements, and research-related activities, although the company remains in a growth and commercialization stage.

The company was founded in 2008 and is headquartered in Salt Lake City, Utah. Sera Prognostics evolved from a research-focused proteomics company into a commercial-stage diagnostics business centered on predictive biomarker technologies for pregnancy management. The company’s strategic positioning is based on its proprietary proteomics and bioinformatics platform, large-scale maternal health datasets, and clinical validation efforts aimed at demonstrating the economic and clinical utility of early risk prediction. Public filings and company disclosures indicate that the company seeks to differentiate itself through clinically validated biomarker discovery and integration with obstetric care pathways.

Business Operations

Sera Prognostics primarily operates through a single business focused on developing and commercializing proteomic diagnostic tests for pregnancy-related conditions. Its core operations include biomarker discovery, laboratory testing services, clinical validation studies, data analytics, and commercial engagement with healthcare providers and payors. The company’s flagship offering, the PreTRM test, is processed through a certified laboratory infrastructure and is intended for use in obstetric care settings. The company also maintains a pipeline of research programs related to maternal and neonatal health conditions, including additional predictive diagnostics using proteomic signatures.

Operations are concentrated in the United States, though the company’s scientific collaborations and intellectual property strategy have broader international relevance. Sera Prognostics controls proprietary datasets, biomarker algorithms, and proteomics-related intellectual property developed through clinical research partnerships and internal R&D. The company has collaborated with healthcare systems, academic institutions, and industry organizations to support validation studies and market adoption initiatives. Public disclosures identify strategic relationships with healthcare providers and research institutions as important to clinical evidence generation and reimbursement efforts.

Strategic Position & Investments

Sera Prognostics’ strategic direction centers on expanding adoption of the PreTRM test, strengthening reimbursement coverage, and generating additional clinical utility data to support broader integration into prenatal care. The company has invested substantially in clinical studies designed to demonstrate reductions in adverse pregnancy outcomes and healthcare costs associated with earlier identification of preterm birth risk. Its commercialization strategy has included engagement with insurers, healthcare systems, and obstetric provider networks to improve awareness and utilization of predictive pregnancy diagnostics.

The company’s investments are concentrated in proteomics research, data analytics capabilities, and clinical evidence generation rather than large-scale acquisitions. Sera Prognostics has highlighted the use of machine learning and bioinformatics tools to analyze protein biomarkers associated with pregnancy outcomes. While the company has not been associated with major acquisition activity relative to larger diagnostics peers, its strategic focus remains aligned with emerging precision medicine trends in women’s health and predictive diagnostics. Data regarding material international investments or extensive subsidiary structures is limited in public filings, and publicly available information indicates the company primarily operates as a focused standalone diagnostics entity.

Geographic Footprint

Sera Prognostics is headquartered in Salt Lake City, Utah, and its commercial and laboratory operations are primarily concentrated in the United States. The company markets its maternal health testing solutions to U.S.-based healthcare providers, health systems, and payors, with an emphasis on integrating predictive diagnostics into domestic prenatal care practices. Public company disclosures indicate that the majority of operational activity, testing services, and commercialization efforts are currently U.S.-focused.

Although the company does not maintain a broad multinational operating structure comparable to large global diagnostics firms, its intellectual property portfolio and clinical research efforts have relevance to international maternal healthcare markets. Its scientific publications, collaborations, and proteomic technologies contribute to visibility within the broader global precision medicine and women’s health sectors. Data regarding significant direct operational footprints outside the United States is inconclusive based on available public sources.

Leadership & Governance

Sera Prognostics was founded by researchers and executives involved in proteomics and maternal health innovation. The company is governed by a board of directors and executive leadership team focused on advancing predictive diagnostics for pregnancy care. Public statements and investor communications emphasize evidence-based commercialization, clinical validation, and healthcare economic outcomes as central components of leadership strategy.

Key executives include:

• Zane Burke – Chief Executive Officer
• Gregory C. Critchfield, M.D., M.S. – Chairman of the Board
• Andrew M. Johnson – Chief Financial Officer
• Molly Campbell – Chief Commercial Officer
• Brianna M. Wright – General Counsel and Corporate Secretary

Leadership communications have consistently emphasized expanding clinical adoption of the PreTRM test, strengthening payer engagement, and positioning the company as a leader in proteomics-driven maternal health diagnostics. Corporate governance practices are outlined in the company’s SEC filings, including its annual reports and proxy statements.